- Home
- BCDA
BCDA
BioCardia Inc.
as 07-26-2024 4:00pm EST
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | SUNNYVALE |
| Market Cap: | 9.4M | IPO Year: | N/A |
| Target Price: | $4.00 | AVG Volume (30 days): | 78.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.62 - $23.25 | Next Earning Date: | 08-07-2024 |
| Revenue: | $468,000 | Revenue Growth: | -65.49% |
| Revenue Growth (this year): | -25.16% | Revenue Growth (next year): | 436.41% |
Latest BioCardia Inc. News
BCDA Breaking Stock News: Dive into BCDA Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
MT Newswires
9 days ago
BioCardia Receives Patent for Morph DNA Transseptal Delivery
GlobeNewswire
10 days ago
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
GlobeNewswire
19 days ago
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction
MT Newswires
2 months ago
Top Premarket Decliners
MT Newswires
2 months ago
BioCardia Receives Patent for Transendocardial Biotherapeutic Delivery Catheter; Shares Rise Pre-Bell
GlobeNewswire
2 months ago
BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach
PR Newswire
2 months ago
Getting smarter: FIA Launches 3-Day Smart Driving Challenge in Samarkand, Powered by Greater Than
Compare BCDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCDA BioCardia Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.